LYPD5: A Protein Targeted for Therapeutic Intervention (G284348)

Target Name: LYPD5

NCBI ID: G284348

LYPD5

LYPD5: A Protein Targeted for Therapeutic Intervention

LYPD5 (HALDISIN) is a protein that is expressed in various tissues throughout the body, including the brain, heart, liver, and kidneys. It is a member of the HAD family of proteins, which are involved in a variety of cellular processes, including cell signaling, DNA replication, and stress response.

Recent studies have identified LYPD5 as a potential drug target (or biomarker) due to its involvement in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In this article, we will explore the biology and potential therapeutic applications of LYPD5.

LYPD5 is a 21-kDa protein that is expressed in the brain, heart, liver, and kidneys. It is composed of a unique N-terminal domain that is involved in protein-protein interactions and a C-terminal domain that contains a variety of functional domains, including a G伪-signaling domain, a K-type channel, and a F-type ATPase. The C-terminal domain is responsible for the protein's unique 50% glycosylation, which is a hallmark of the HAD family of proteins.

LYPD5 is involved in a variety of cellular processes that are crucial for maintaining cellular homeostasis. One of its most well-known functions is its role in the DNA replication process. LYPD5 is a component of the DNA replication machinery, which is responsible for copying the genetic information of the cell's DNA to create a new copy. During DNA replication, LYPD5 plays a critical role in the formation of double-stranded DNA structures, which are necessary for the replication process to occur.

In neurodegenerative diseases, LYPD5 has been observed to be aberrantly expressed or deleted, which may contribute to the development and progression of these diseases. For example, studies have shown that LYPD5 is overexpressed in the brains of patients with Alzheimer's disease, and that this overexpression is associated with the progression of the disease. Similarly, LYPD5 has also been observed to be deleted in the brains of Parkinson's disease patients.

In addition to its role in DNA replication, LYPD5 is also involved in cell signaling and stress response. It has been shown to play a role in the regulation of cellular stress responses, and in the regulation of cellular signaling pathways that are involved in cell growth , differentiation, and survival.

LYPD5 has also been identified as a potential drug target due to its involvement in several diseases, including cancer. For example, studies have shown that LYPD5 is overexpressed in various types of cancer, and that this overexpression is associated with the development and progression of these diseases. Additionally, LYPD5 has also been shown to play a role in the regulation of cellular signaling pathways that are involved in cancer growth and progression.

In conclusion, LYPD5 is a protein that is involved in a variety of cellular processes that are crucial for maintaining cellular homeostasis. Its unique N-terminal domain, C-terminal domain, and double-stranded DNA formation capabilities make it an attractive target for therapeutic intervention. Its involvement in DNA replication, neurodegenerative diseases, cancer, and stress response make it a promising drug target for the development of new treatments. Further research is needed to fully understand the biology and therapeutic applications of LYPD5, and to develop safe and effective drugs that can target this protein.

Protein Name: LY6/PLAUR Domain Containing 5

The "LYPD5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LYPD5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets